Full Press Release Details
Preclinical Data Demonstrates Potential Of Eidos Therapeutics' Lead Compound For The Treatment For Transthyretin Amyloidosis.
BBIO
Preclinical Data Demonstrates Potential Of Eidos Therapeutics' Lead Compound For The Treatment For Transthyretin Amyloidosis
Key Takeaway: Preclinical Data Demonstrates Potential Of Eidos Therapeutics' Lead Compound For The Treatment For Transthyretin Amyloidosis